Simmons, Bryony

Dolutegravir plus two different prodrugs of tenofovir to treat HIV

Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 723

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014) · Clinical Infectious Diseases

Hepatitis C virus researchPharmaceutical Economics and Policy

Cited by 216

Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes

McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021) · AIDS

HIV-related health complications and treatmentsHIV/AIDS drug development and treatment

Cited by 72